Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice, 12968 [2017-04529]
Download as PDF
<![CDATA[
12968
Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
As a general matter, information
collections will not result in any new
system of records containing privacy
information and will not ask questions
of a sensitive nature, such as sexual
behavior and attitudes, religious beliefs,
and other matters that are commonly
considered private.
Households, Businesses, Organizations,
and/or State, Local or Tribal
Government. There is no cost to
respondents other than their time. The
estimated annualized burden hours for
this data collection activity are 9,690.
This is a revision to the previously
approved collection to reduce the
burden hours from 12,400 to 9,690
hours as a result of the previous usage
and anticipated future usage of this
Generic Information Collection.
Respondents will be screened and
selected from Individuals and
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of collection
Annual
frequency
per response
Hours
per response
Total hours
Online surveys .................................................................................................
Discussion Groups ...........................................................................................
Focus groups ...................................................................................................
Web site/app usability testing ..........................................................................
Interviews .........................................................................................................
10,500
280
640
2,000
800
1
1
1
1
1
30/60
2
2
30/60
2
5,250
560
1280
1,000
1,600
Totals ........................................................................................................
14,220
........................
........................
9,690
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). Please call the
Information Line for up-to-date
information on this meeting.
[FR Doc. 2017–04510 Filed 3–7–17; 8:45 am]
In the
Federal Register of January 11, 2017 (82
FR 3333), FDA announced that the joint
meeting of the Drug Safety and Risk
Management Advisory Committee and
the Anesthetic and Analgesic Drug
Products Advisory Committee would be
held on March 13–14, 2017. On page
3334, in the first column, under the
ADDRESSES caption, the address of the
meeting and the phone number in the
first six lines is changed to read as
follows:
SUPPLEMENTARY INFORMATION:
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0067]
Joint Meeting of the Drug Safety and
Risk Management Advisory Committee
and the Anesthetic and Analgesic Drug
Products Advisory Committee;
Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
amendment to the notice of the joint
meeting of the Drug Safety and Risk
Management Advisory Committee and
the Anesthetic and Analgesic Drug
Products Advisory Committee. This
meeting was announced in the Federal
Register of January 11, 2017. The
amendment is being made to reflect a
change in the ADDRESSES portion of the
document. There are no other changes.
FOR FURTHER INFORMATION CONTACT:
Stephanie L. Begansky, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533, email:
AADPAC@fda.hhs.gov, or FDA
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:34 Mar 07, 2017
Jkt 241001
The meeting will be held at
the Tommy Douglas Conference Center,
10000 New Hampshire Ave., Silver
Spring, MD 20903. The conference
center’s telephone number is 240–645–
4000.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
ADDRESSES:
Dated: March 3, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2017–04529 Filed 3–7–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Notice To Propose the Re-Designation
of the Service Delivery Area for the
Passamaquoddy Tribe at Indian
Township
Indian Health Service, HHS.
Notice.
AGENCY:
ACTION:
This notice advises the public
that the Indian Health Service (IHS)
proposes to expand the geographic
boundaries of the Purchased/Referred
Care (PRC) Service Delivery Area (SDA)
for the Passamaquoddy Tribe’s
reservation at Indian Township
(Passamaquoddy at Indian Township or
Tribe) in Maine. This notice does not
propose to change or expand the PRC
SDA for the Tribe’s Pleasant Point
reservation. This notice only relates to
the expansion of the Tribe’s PRC SDA
for the Indian Township reservation.
DATES: Comments must be submitted
April 7, 2017.
ADDRESSES: You may submit comments
in one of four ways detailed below.
However, we cannot accept comments
by facsimile (FAX) transmission due to
staff and resource limitations. Please
choose one method below:
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a Comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Betty Gould, Regulations
Officer, Indian Health Service, 5600
Fishers Lane, Mailstop: 09E70,
Rockville, Maryland 20852. Please allow
sufficient time for mailed comments to
SUMMARY:
E:\FR\FM\08MRN1.SGM
08MRN1
]]>Agencies
[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Page 12968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04529]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0067]
Joint Meeting of the Drug Safety and Risk Management Advisory
Committee and the Anesthetic and Analgesic Drug Products Advisory
Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of the joint meeting of the Drug Safety and
Risk Management Advisory Committee and the Anesthetic and Analgesic
Drug Products Advisory Committee. This meeting was announced in the
Federal Register of January 11, 2017. The amendment is being made to
reflect a change in the ADDRESSES portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT: Stephanie L. Begansky, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: AADPAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area). Please call the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of January 11, 2017
(82 FR 3333), FDA announced that the joint meeting of the Drug Safety
and Risk Management Advisory Committee and the Anesthetic and Analgesic
Drug Products Advisory Committee would be held on March 13-14, 2017. On
page 3334, in the first column, under the ADDRESSES caption, the
address of the meeting and the phone number in the first six lines is
changed to read as follows:
ADDRESSES: The meeting will be held at the Tommy Douglas Conference
Center, 10000 New Hampshire Ave., Silver Spring, MD 20903. The
conference center's telephone number is 240-645-4000.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: March 3, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-04529 Filed 3-7-17; 8:45 am]
BILLING CODE 4164-01-P
